Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Urology, PLLC

Neither a doctor nor a teaching hospital

Research payments

$1,688,900

14 payments

Through program year 2025, Advanced Urology, PLLC is reported as receiving $1,688,900 in research payments, across 14 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $908,368 4
2024 Research $536,477 4
2023 Research $56,720 1
2022 Research $113,887 2
2021 Research $10,957 1
2019 Research $62,491 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,279,591 9 payments
  2. AstraZeneca UK Limited $346,818 3 payments
  3. AbbVie, Inc. $62,491 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 $530,412 1 payment
  2. a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco $475,914 2 payments
  3. A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) $336,218 2 payments
  4. A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) $272,247 5 payments
  5. M16-100 $62,491 2 payments
  6. A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib and Docetaxel Versus Placebo and Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) $10,600 1 payment
  7. A Randomised,Double blind,Placebo controlled,Adaptive,Population Enrichment Phase III Study of AZD5305 in Men with Metastatic Castration sensitive Prostate Cancer Receiving Physician is Choice New Hormonal Agents $1,019 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record